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ABSTRACT
Phosphoglycerate mutase (PGAM), a conserved, glycolytic enzyme has been 
found in nucleoli of cancer cells. Here, we present evidence that accumulation of 
PGAM in the nucleolus is a universal phenomenon concerning not only neoplastically 
transformed but also non-malignant cells. Nucleolar localization of the enzyme is 
dependent on the presence of the PGAM2 (muscle) subunit and is regulated by insulin/
IGF-1–PI3K signaling pathway as well as drugs influencing ribosomal biogenesis. We 
document that PGAM interacts with several 40S and 60S ribosomal proteins and that 
silencing of PGAM2 expression results in disturbance of nucleolar structure, inhibition 
of RNA synthesis and decrease of the mitotic index of squamous cell carcinoma cells. 
We conclude that presence of PGAM in the nucleolus is a prerequisite for synthesis 
and initial assembly of new pre-ribosome subunits.
INTRODUCTION
Over the last twenty years, it has been demonstrated 
that evolutionarily old enzymes of carbohydrate 
metabolism are present not only in cytoplasm but also in 
the cell nucleus or mitochondria. In these compartments, 
they are engaged in regulation of many basic cellular 
processes such as proliferation, differentiation or 
programmed cell death, and their biological activity is not 
necessarily restricted to catalytic activity.
One of them is phosphoglycerate mutase (PGAM, 
EC 5.4.2.1), a conserved, glycolytic enzyme which 
catalyses reversible conversion of 3-phosphoglycerate 
to 2-phosphoglycerate. Mammalian PGAM consists of 
two subunits, called muscle (M or PGAM2) and brain 
(B or PGAM1). PGAM has three isozymes: muscle-type 
(PGAM-MM), brain-type (PGAM-BB) homodimers or 
a heterodimer (PGAM-MB). In different tissues, various 
proportions of these dimers are detected, but most mouse 
cells contain the heterodimeric form [1]. 
In cancer cells, the enzyme appears to be a central 
element of a glycolytic macromolecular complex 
composed of enzymes of triose phosphate metabolism and 
regulated by lactate. Surprisingly, in these cells, PGAM 
was also found in nucleolar structures [2].
The nucleolus is traditionally associated with the 
synthesis and assembly of ribosome subunits. However, 
evidence has accumulated that this structure has additional 
regulatory functions. In human nucleolar proteome, 
one can find proteins involved not only in ribosome 
biogenesis but also in regulation of cell cycle and stress 
responses (reviewed in [3]). Proteomic studies have also 
demonstrated the presence of glycolytic and pentose 
phosphate pathway enzymes in nucleoli [4], but these 
authors did not discuss the physiological relevance of such 
localization. Instead, the authors’ comments suggested 
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that they expected a “classical” metabolic role of these 
enzymes in nucleoli.
To address the question concerning the role 
of PGAM in nucleolus, we have sought to identify 
signaling pathways regulating PGAM localization in this 
compartment and to identify nucleolar proteins interacting 
with the enzyme. We have also tested the effect of PGAM 
silencing on the nucleolar structure and function. We have 
observed that PGAM2 subunit is crucial for nucleolar 
localization of PGAM homo- and heterodimers. Results 
presented here demonstrate that PGAM is directed to 
nucleoli of neoplastically transformed and non-malignant 
cells by insulin/IGF-1/PI3K signaling pathway and 
appears to interact with ribosomal proteins. The silencing 
of the PGAM2 expression results in disturbance in 
nucleolar structure as well as in inhibition of RNA 
synthesis. Together, our findings suggest that PGAM2 is 
a crucial part of the mechanism of nucleolar response to 
growth factors and may be a target in some transformed 
cells which grow in response to aberrant IGF-1/PI3K 
signaling.
RESULTS
Detection of PGAM in nucleoli
As we have demonstrated before [2], incubation 
of KLN-205 cells with polyclonal antibodies directed 
to the whole PGAM protein resulted in strong staining 
of cytoplasm, much weaker staining of nucleus and no 
staining of some subnuclear compartments (Figure 1A) 
of these cells. However, after incubation of the KLN-
205 cells with antibody directed towards the C-terminal 
peptide of PGAM, the immunoreaction was found mainly 
in the subnuclear compartments (Figure 1A). These 
compartments were identified as the nucleoli since they 
were propidium-iodide(PI)-positive in untreated cells, but 
PI-negative in cells treated with RNase (Figure 1B).
Similar strong nucleolar staining was observed also 
in histological sections of human breast cancer (BC), in 
primary cultures of neoplastically transformed cells of 
human non-small cell lung carcinoma (NSCLC), and also 
in non-malignant cells (cultured mouse astrocytes and 
HL-1 cardiomyocytes), incubated with antibody against 
the C-terminal PGAM peptide (Figure 2).
It has been suggested that the observed differences 
in immunostaining between these two types of antibodies 
result from the inability of the antibodies against the whole 
PGAM molecule to detect its C-terminal peptide rather 
than from an unspecific reaction of the antibody against 
the C-terminus of PGAM with some nucleolar antigens 
[2]. However, this might imply that PGAM in nucleoli is 
tightly surrounded by other proteins or nucleic acids and 
in consequence, only the C-terminal region of the enzyme 
is available to antibodies.
To verify this, the KLN-205 cells were treated with 
RNase A prior to fixation and incubation with antibodies 
against the whole PGAM molecule. After such treatment 
Figure 1: Detection of PGAM in KLN-205 cells with antibodies directed to whole PGAM protein or to C-terminal 
peptide of PGAM. A. control conditions (scan parameters in red channel were set to emphasize nucleolar staining with propidium iodide 
– PI) B. RNase-treated cells. Bar=15 µm.
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nucleolar presence of PGAM was detected in about 60% 
of the cells (Figure 1B). However, at the same time, 
staining of the nucleoli with the PGAM C-terminus-
specific antibodies became less intensive (Figure 1B). 
Together, this might indicate that although the nucleolar 
RNA is a factor reducing the availability of PGAM to 
antibodies, and it is also – a direct or indirect – binding 
partner of the protein.
To unequivocally confirm nucleolar localization 
of PGAM, we sought for the presence of the enzyme 
in sucrose gradient-isolated nucleoli of the KLN-205 
cells using mass spectrometry. The analysis revealed 
the presence of peptides specific for the brain and 
muscle PGAM subunits (PGAM1 and 2), as well as 
PGAM5 (Supplementary Figure 1). PGAM5 lacks 
phosphoglycerate mutase activity acting instead as a 
Ser/Thr protein phosphatase [5] and was classified as a 
nucleolar polypeptyde folding factor [6]. 
Identification of the signaling pathways regulating 
nucleolar localization of PGAM
In KLN-205 and NSCLC cells cultured in the 
absence of serum, immunocytochemical methods failed 
to detect PGAM in nucleoli of the majority of the cells 
(Figure 3), suggesting that regulation of the PGAM 
presence within these substructures was due to some 
serum-derived factors. In such conditions, antibodies 
directed to the C-terminus of PGAM stained mainly 
cytoplasm and, in about 1% of cells, outer region of 
nucleoli and also nucleus. In other types of examined cells, 
serum starvation also resulted in reduction of nucleolar 
PGAM and detection of the C-terminus of the protein both 
in cytoplasm as well as whole nucleus (Figure 3).
Not surprisingly, in the serum-deprived cultures, 
mitotic figures were not observed indicating cessation of 
proliferation (data not shown).
In line with this, the mass spectrometry analysis 
of nucleoli isolated from KLN-205 cells cultured in the 
Figure 2: Subcellular localization of PGAM with the use of antibody directed to C-terminal peptide of the protein. The 
localization was examined in cultures of non-small cell lung carcinoma (NSCLC) HL-1 cardiomyocytes, astrocytes and in breast cancer 
tissue section (BC). Arrows point nucleoli. Bar=5 µm.
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absence of serum identified only the PGAM5-derived 
peptides (Supplementary Figure 1). Together, these results 
provided evidence that in serum-free culture conditions, 
PGAM was absent from nucleoli. 
After 24h culture of the KLN-205 cells in the serum-
free medium supplemented with insulin, the proliferation 
was resumed and PGAM re-appeared in nucleoli, as 
demonstrated with the use of antibodies directed to the 
C-terminal region of the enzyme. This re-appearance 
was relatively slow and in some cells, whole PGAM-
positive nuclei were observed or PGAM was present 
mainly in outer region of nucleoli (forming cap-like 
structures) (Figure 4). Similar effects were obtained after 
supplementation of the serum-free medium with IGF-1 
(Figure 4). However, if insulin was added together with 
an inhibitor of PI3K (wortmannin) which is a downstream 
target of insulin signaling, nucleolar localization of PGAM 
was not detected (Figure 4). In majority of the cells, the 
serum withdrawal effected also changes of nucleolar 
amount and morphology: instead of 2-3 nucleoli, only 
one enlarged nuclear subcompartment/substructure was 
observed. In some of the cells, these changes lasted even 
during insulin/IGF-1 replenishment (Figure 4). 
Likewise, in non-transformed cells (astrocytes), 
replenishment of serum-free medium with insulin 
was sufficient to induce the re-appearance of PGAM 
in nucleoli. However, the process was faster than in 
malignant cells and we did not observe the cap-like 
structures; in contrast the mitotic figures were more 
numerous than in the malignant cells (Suppl. Figure 4A).
The effect of drugs inhibiting ribosome biogenesis 
on PGAM subcellular localization
Incubation of the KLN-205 cells with roscovitine 
which blocks proliferation acting as an inhibitor of 
cyclin-dependent kinases [7], resulted in spreading of 
Figure 3: Localization of PGAM with the use of antibody against the C-terminal peptide in neoplastically transformed 
(NSCLC, KLN-205) and non-malignant (HL-1 cardiomiocytes, astrocytes) cells cultured in serum-free media. Bar=10 
µm.
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nucleolar apparatus into necklace-like structures. In these 
conditions, while irregular in shape – but PGAM- and PI-
positive, structures could still be observed (Figure 5). 
After treatment of KLN-205 cells with etoposide – 
a topoisomerase II inhibitor inducing DNA damage but 
also influencing nucleolar protein content [8], a weak 
immunofluorescent signal of PGAM was observed in 
nuclei and in nucleolar cap-like structures (Figure 5). 
Central regions of nucleolus were devoid of PGAM 
staining.
After a brief exposure of the KLN-205 cells to low 
concentrations (0.04 µg/ml) of actinomycin-D (ActD) 
– which is known to selectively reduce rRNA synthesis 
and induce release of nucleolar protein to nucleoplasm 
[9], PGAM was redistributed to cap-like structures and 
was absent from central regions of nucleoli (Figure 5). 
These regions exhibited also lack of staining with PI, 
which suggests an absence of RNA there. Treatment of 
the cells with relatively high concentration of ActD (2.5 
µg/ml) which completely blocks DNA transcription 
resulted in a rather homogeneous nuclear localization of 
PGAM, as determined with the use of antibodies against 
the C-terminus (Figure 5).
To determine if ActD action-associated export of 
PGAM from nucleoli correlated with changes in cell cycle 
phase we used the Premo™ FUCCI Cell Cycle Sensor 
which allows imaging of cell cycle progression. However, 
the KLN205 cells appeared to be hardly transfectable 
and we observed the sensor-related signal only in a 
small proportion of the cells. Thus, we decided to use the 
NSCLC cells, testing first response of their nucleolar pool 
of PGAM to ActD. As in the previous cells, such treatment 
of NSCLC resulted in redistribution of PGAM to nucleolar 
cap structures or in homogeneous nuclear presence of the 
enzyme, depending on ActD concentration (Figure 6).
NSCLC cells transfected with FUCCI reagent and 
exposed overnight to 0.04 µg/ml of ActD appeared to be 
blocked in the late G2 phase, since the nuclei and also 
cytoplasm of majority of the cells exibited intense green 
fluorescence. This was in line with the data published 
by Ma and Pederson [9] demonstrating that ActD elicits 
nucleolar stress and blocks cells in very late interphase. 
In the untreated NSCLC cells, the fluorescence of the 
majority of nuclei pointed to G1 (red fluorescence) or 
G1/S (yellow fluorescence) phase (Figure 6). 
These observations indicated that a lack of nucleolar 
PGAM was correlated with the G2/M cell cycle blockade 
and inhibition of rRNA synthesis.
Transfection of the KLN-205 cells with PGAM2-
FITC
Transfection of the KLN-205 cells with 
fluorescently-labeled PGAM2 in the presence of serum 
in culture medium resulted in predominantly cytoplasmic 
accumulation of the enzyme (Figure 7). Labeling of 
nuclei was relatively weak and no specific localization 
in nuclear substructures was observed. Assuming that 
nucleolar PGAM2 is tightly bound in a protein and/or 
RNA complex, the lack of the native-to-labeled PGAM2 
molecule exchange might point to high stability of this 
complex. When PGAM2-FITC was accompanied with 
RNase A, the PGAM2 molecules were more readily 
exchanged and nucleolar localization of the enzyme 
was observed (Figure 7). FITC-labeled BSA introduced 
into the KLN-205 cells (as a control) with the use of 
ProteoJuice, localized diffusely within cytoplasm of the 
cells (Figure 7).
Silencing of PGAM2 gene expression
The antibodies against the C-terminus of PGAM do 
not allow the distinction between the brain (PGAM1) and 
Figure 4: Localization of PGAM in KLN-205 cells in different culture conditions. PGAM was localized with the use of 
antibody against the C-terminal peptide of the protein in the cells cultured in serum-free medium re-supplemented with IGF-1, insulin or 
insulin and inhibitor of PI3K (wortmannin). Bar=15 µm.
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muscle (PGAM2) isoform. PGAM2 isoform is much less 
abundant in tissues (except muscle tissue; Table 1) than 
PGAM1, and these low titers of PGAM2 may suggest that 
the isoform does not play any significant physiological 
role in a cell. However, concentration of PGAM2 is 
similar or higher than titers of proteins involved in 
ribosome biogenesis, e.g. DNA-directed RNA polymerase 
I (Suppl. Table 1). 
Thus, we used a commercially prepared siRNA to 
silence expression of the PGAM2 gene in KLN-205 cells 
and tested the effects of the silencing on structure and 
function of nucleoli. 
PCR reaction with the use of PGAM1- and PGAM2-
specific primers revealed about 3.7-fold decrease of the 
PGAM2 mRNA amount in the PGAM2-silenced cells 
as compared to control cells. No visible difference was 
observed in the amount of PGAM1 mRNA (Suppl. Figure 
2).
Immunofluorescent reactions failed to detect PGAM 
in nucleoli of PGAM2-silenced cells (Figure 8A). This 
indicated that the PGAM2 subunit was indispensable for 
nucleolar localization of PGAM dimer and hence, nucleoli 
may contain both PGAM2 homodimers and PGAM2/
PGAM1 heterodimers, but not PGAM1 homodimers.
In most of the cells with silenced PGAM2 
expression, only one, centrally located nucleolus was 
observed (Figure 8A). Additionally, the shape of such 
nucleolus (and whole nucleus) was often distorted. 
To determine if the decline of PGAM2 protein 
influenced nucleolar function, we examined the level of 
Figure 5: Localization of PGAM with antibody directed to the C-terminal peptide of the protein in nuclei of KLN-205 
cells treated with drugs disturbing ribosomal biogenesis. ActD – actinomycin D; PI – propidium iodide. Bar=5 µm.
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RNA production in PGAM2-silenced and control cells 
using a click chemistry–based fluorescence tagging 
procedure (see Methods). As a result, we observed 
a significant reduction of RNA signal resulting from 
nucleolar compartment of PGAM2- silenced cells 
(Figure 8B) pointing to diminished transcription of 
rDNA (i.e. diminished production of ribosomal RNA). 
The global level of RNA synthesis was also reduced. We 
also observed increased intensity of activated caspase-3 
immunostaining (Suppl. Figure 3) and 4.6-fold decrease 
of mitotic index (not shown) in PGAM2- silenced cells 
compared to control cells.
Similar reduction of RNA synthesis was observed 
also in PGAM2-silenced non-malignant cells, HL-1 
cardiomyocytes (Suppl. Figure 4B).
Moreover, 72 h after transfection with siRNA we 
observed almost 2-fold decrease of cell number and over 
20% reduction of protein concentration per one cell in 
cultures of PGAM2-silenced cells (KLN-205 as well 
as HL-1), as compared to cultures of cells treated with 
control, non-silencing siRNA. 
Figure 6: Correlation of ActD-stimulated changes of PGAM localization in NSCLC cells with blockade of the cell cycle 
cell in G2 phase. Upper panel: the PGAM2 localization in the cells incubated with 0.04 µg/ml (low) or 2.5 µg/ml (high) actinomycin D 
(ActD). Lower panel: the cells in G1 (red) and G1/S (yellow) phase in control conditions and blockade of the ActD-treated cells in G2 phase 
(green fluorescence) as determined by FUCCI Cell Cycle Sensor. Bar=10 µm.






Brain 56 ± 14 0.86 ± 0.59 3 65
Ovary 32 ± 11 0.93 ± 0.23 3 35
Thymus 15 ± 7.8 0.21 ± 0.066 2 74
Thyroid 13 ± 2.9 34.9 ± 5.8 3 0.38
Red muscle 0.54 ± 0.14 97.23 ± 22.4 4 0.0055
White muscle 0.17 ±0.11 178 ± 26 4 0.00095
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PGAM-interacting nucleolar proteins
The MS analysis of PGAM-interacting proteins in 
nucleoli of KLN-205 cells revealed that the enzyme may 
interact with constituent proteins of 40S and 60S ribosomal 
complexes, proteins involved in ribosome biogenesis and 
post-translational modifications (e.g. with ribosome-
associated chaperones, such as peptidyl-prolyl cis-trans 
isomerase B) and proteins linking the nucleolar stress with 
cell cycle regulation and apoptosis (e.g. RPS27a and L26 
protein) [10-12] (Table 2). PGAM associates with several 
members of 14-3-3 adapter proteins family (14-3-3 zeta/
delta, sigma, beta/alfa, teta) of which the yeast homolog 
– Bmh2 (http://www.yeastgenome.org/cgi-bin/protein#), 
was shown to attenuate the repression of genes involved 
in ribosome biogenesis [13].
DISCUSSION 
In the present paper, we have demonstrated, using 
several lines of evidence, that a glycolytic enzyme – 
phosphoglycerate mutase, is present in nucleoli of non-
transformed as well as neoplastically transformed cells. 
The enzyme is directed to nucleoli of cancer cells by 
insulin/IGF-1–PI3K signaling pathway, and appears 
to interact with the ribosomal proteins. The lack of the 
nucleolar PGAM is correlated with G2/M cell cycle 
blockade and the silencing of PGAM2 gene expression 
Figure 7: The effects of KLN-205 cells transfection with PGAM2. The cells were transfected with PGAM2-FITC in normal 
conditions and in the presence of RNase. As a control, cells were transfected with BSA-FITC. Bar=10 µm.
Table 2: PGAM-interacting nucleolar proteins detected with affinity chromatography 
and subsequent mass spectrometry analysis.



















40S ribosomal protein S16 188 11 P14131
60S acidic ribosomal protein P0 132 8 P14869
40 ribosomal protein S3 99 8 P62908
60S ribosomal protein L8 95 6 P62918
60S ribosomal protein L18 92 5 P35980
40S ribosomal protein S14 91 7 P62264
histone H3.3C 88 13 P02301
peptidyl-prolyl cis-trans isomerase B 71 6 P24369
peptidyl-prolyl cis-trans isomerase A 70 5 P17742
60S ribosomal protein L26 69 8 P61255
40S ribosomal protein S18 63 7 P62270
40S ribosomal protein S6 59 3 P62754
ubiquitin-40S ribosomal protein S27a 44 5 P62983
60S ribosomal protein L10a 43 7 P53026
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resulted in structural changes within nucleoli, inhibition 
of RNA expression and the reduction of cellular protein 
content.
The nucleolus is the site of production of ribosomes. 
However, over the last years, proteomic studies have 
demonstrated the presence in the nucleolus of a large 
number of proteins which were not typically considered 
as a part of rDNA transcription and processing machinery. 
Most of these proteins regulate cell proliferation, stress 
response and aging [3]. 
Yet, among the nucleolar proteins, enzymes of 
carbohydrate metabolism – glycolysis and pentose 
phosphate pathway, have been found [4]. The 
physiological meaning of such localization has not 
been explained: both the “classical” metabolic role and 
the potential additional function of these enzymes in 
nucleolus remain unclear. It has been suggested that the 
nucleolus may act as a regulator of protein activity – just 
by their sequestration [14] However, since all glycolytic 
enzymes are highly abundant proteins in a cell [15], the 
“sequestration for inhibition” theory sounds improbable. 
In the cytoplasm of cancer cells, the C-terminus 
of the PGAM molecules is involved in maintaining the 
enzyme in its active form [16] and in association with 
other enzymes of glycolytic complex and thus, it is 
unavailable to antibodies [2]. In the present work, we 
Figure 8: The effects of PGAM2 silencing on nucleolar morphology and new RNA production in KLN-205 cells. A. in 
PGAM2-silenced cells, unlike control cells, stained with propidium iodide (red), only one centrally located nucleolus can be found and 
nucleolar PGAM staining (green) is undetectable; B. the level of new RNA (red) synthesis in PGAM2-silenced cells is reduced as compared 
to control cells. To visualize DNA the cells were counterstained with Hoechst 33342 (blue). Bar=10 µm.
Oncotarget17246www.impactjournals.com/oncotarget
demonstrated that in nucleoli of not only cancer but 
also non-transformed cells, PGAM seems to be tightly 
surrounded by other proteins and/or nucleic acids and 
only the C-terminus of this enzyme is available to anti-
PGAM antibodies (Figures 1, 2). The results of the protein 
transfection experiment suggest that this association is 
quite stable. Only the digestion of nucleolar structures 
with RNase made the whole PGAM protein more readily 
accesible to antibodies as well as to the process of 
exchange of the native to FITC-labeled PGAM molecules 
(Figure 1B and 7). This indicates that the rRNA presence 
is not prerequisite to the nucleolar localization of PGAM, 
although some interactions between the two components 
cannot be excluded. And since a tight interaction of 
C-terminal peptide of PGAM with its central part is needed 
to maintain the enzyme in the active form [16], thus the 
exposition of the C-terminus to antibodies suggests 
that nucleolar PGAM is constantly in its enzymatically 
inactive state. Previously, we have demonstrated that 
the nucleolar localization of PGAM was independent of 
concentration of glucose metabolites [2]. In the present 
work, we did not observe any of the glycolytic enzymes 
among the potential binding partners of nucleolar PGAM. 
Thus, together, the data suggests that the nucleolar role(s) 
of PGAM are different from the cytoplasmic functions 
and not related to the catalytic activity of this enzyme. 
However, to unequivocally prove this, further studies 
using catalytically inactive PGAM2 mutants are needed.
In the present paper, we showed that serum 
starvation, which results in cessation of proliferation, 
resulted also in withdrawal of PGAM from nucleoli 
(especially from their central regions), and that activation 
of the insulin/IGF-1–PI3K pathway in the serum-depleted 
cells was sufficient for nucleolar re-accumulation of 
PGAM (Figures 3, 4). 
Serum starvation is known to cause disruption of 
rDNA transcription and ribosome biogenesis which finally 
results in the cell cycle arrest. It has been demonstrated 
that these changes are an effect of insulin deficiency. 
Insulin regulates the nuclear content of upstream binding 
factor (UBF) and RNA polymerase I-associated factor 
(PAF) 53 which are required for assembly of RNA 
polymerase I into an active complex. As a result, insulin 
stimulation rises the steady-state number of ribosomes 
within a cell [17]. It has been also shown that activity 
of the IGF-1–PI3K pathway is essential to induction of 
polymerase I [18].
Therefore, we tested the relationship between 
nucleolar PGAM and ribosome biogenesis. After 
silencing of PGAM2 expression in cells, complete lack 
of nucleolar PGAM immunoreactivity was observed 
(Figure 8A). This indicated that although both PGAM1 
and PGAM2 isoforms were present in nucleoli (Suppl. 
Figure 1), the PGAM2 subunit was indispensable for 
nucleolar localization of the PGAM dimer. What was 
more intriguing, the absence of PGAM in nucleoli tightly 
correlated with reduction of the number of nucleoli (only 
one, large, centrally located, and often distorted nucleolus 
was observed in majority of the cells; Figures 4, 5, 8), 
inhibition of RNA synthesis (Figure 8, Suppl. Figure 4B), 
decrease of mitotic index and reduction of cellular protein 
content. This strongly suggests that the biogenesis of 
ribosomes depends on nucleolar localization of PGAM. 
In search for further evidence that nucleolar 
localization of PGAM correlates with rDNA transcription 
and/or rRNA processing, we treated cells with 
chemotherapeutic drugs known to disturb ribosomal 
biogenesis at the level of transcription (ActD) and early 
or late rRNA processing (roscovitine and etoposide, 
respectively) [19]. A brief treatment of cells with low 
concentrations of ActD resulted in release of nucleolar 
proteins to nucleoplasm [20]. Under such conditions, 
nucleoli are depleted of RNA polymerase I, ribosomal 
proteins and exosome components [21] and the amount 
of nucleolar RNA is strongly diminished. We found that 
after the ActD treatment, PGAM immunoreactivity in 
central regions of nucleoli was significantly reduced 
and the enzyme was redistributed to nucleolar cap 
structures (Figure 5). This suggests that PGAM is a 
component of rDNA transcription machinery. On the 
other hand, inhibition of early rRNA processing with 
roscovitine resulted in spreading of nucleolar apparatus 
and localization of PGAM into so-called necklace-like 
structures (Figure 5). Although appearance of these 
structures is a sign of disruption of ribosome biogenesis, 
some synthesis of 45S rRNA must continue to maintain 
the necklace morphology [22]. Thus, the presence of 
PGAM2 in the necklace-like nucleoli might narrow the 
enzyme function to transcription of 45S rDNA.
The inhibition of late rRNA processing with 
etoposide resulted again in reduction in nucleolar PGAM 
immunoreactivity (Figure 5). 
Such changes in PGAM nucleolar distribution 
during inhibition of pre-ribosome biogenesis indicates 
that the enzyme is involved in the proper functioning of 
all stages of pre-ribosome production machinery. In line 
with this, the mass spectrometry analysis of nucleolar 
PGAM binding partners revealed that PGAM may interact 
with several 40S and 60S ribosomal proteins (Table 2). 
Among potential interaction partners are ribosomal 
proteins with extra ribosomal functions, such as L26 and 
RPS27a. Both of these proteins in their free cytoplasmic 
form are involved, though by different mechanisms, in 
elevation of cellular levels of p53 protein and induction 
of apoptosis [10, 12]. Reduction of pre-ribosome integrity 
in the PGAM2-silenced cells might therefore increase the 
availability of these proteins and facilitate activation of the 
p53-dependent cell response to disturbance of ribosome 
biogenesis. The increased immunoreactivity of activated 
caspase-3 observed in PGAM2-silenced cells appears 
to support this hypothesis (Suppl. Figure 3). To the best 
of our knowledge, PGAM has not been found in mature 
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ribosomes (http://www.lamondlab.com/NOPdb3.0) and 
hence, the role of the enzyme seem to be essential for 
biogenesis but not to further functioning of ribosomes. 
Efficient ribosome biogenesis is crucial in animal 
cells undergoing rapid proliferation but it is also an energy-
consuming process. Reduction of nutrient availability 
leads to decrease in ribosome subunit production. Thus, 
one can argue that silencing of PGAM2 can influence the 
nucleolar function just by reducing the glycolytic flux 
and cellular pool of ATP. However, as we demonstrated 
above (Table 1), in non-muscle cells, the PGAM2 isoform 
is much less abundant than PGAM1 protein and it is 
unlikely that this isoform may significantly affect the 
glycolytic flux. Therefore, the effect of PGAM2 silencing 
on the nucleolus is most probably not related to energy 
deprivation. 
The canonical insulin and IGF-1 signaling pathway 
induced by PI3K is associated with regulation of cellular 
metabolism and survival. Targeting of this pathway is 
considered in the context of cancer treatment and there 
is accumulating evidence that mutation of PI3KCA 
(PI3K) contributes to the development of many types of 
malignancies [23-24]. Inhibition of the kinase suppresses 
metastasis, mainly through cytostatic effects. However, 
the effectiveness of treatment with a single PI3K inhibitor 
has been questioned [24]. Similarly, results of clinical 
trials using IGF-1 receptor-specific antibodies for cancer 
treatment are disappointing [25].
Both insulin and IGF-1 acting via PI3K (this work 
and [18], respectively) control ribosome biogenesis and 
thereby protein production and cell growth. According 
to our results, this effect is exerted partially through 
directing of PGAM2 to the nucleolus, which is a 
prerequisite for synthesis and initial assembly of new 
pre-ribosome subunits, before their transfer to the nucleus 
and cytoplasm. In the absence of nucleolar PGAM, the 
efficiency of processing and export of pre-ribosomal 
subunits is compromised, resulting in the distortion of 
the nucleolar structure and decline of cellular RNA and 
protein synthesis. Thus, direct targeting of PGAM2 
transport to nucleoli might be worth considering as a part 
of a new anti-cancer combination therapy.
MATERIALS AND METHODS
Cell lines and chemicals
The murine squamous cell carcinoma line KLN-
205 was obtained from ECACC, Europe. The HL-1 
cardiomyocyte cell line was a gift from Dr. W.C. Claycomb 
(Louisiana State University Health Science Center, New 
Orleans, LA, USA). Goat antibodies specific to C-terminal 
peptide of PGAM (NB100-774) were from Novus 
Biologicals. ProteoJuice Protein Transfection Reagent was 
from Merck Millipore. Fluoshield Fluorescent Mounting 
Medium was from Dako. Lipofectamine® 2000, Premo™ 
FUCCI Cell Cycle Sensor and Click-iT® RNA Alexa 
Fluor® 594 Imaging Kit were from Life Technologies. 
NHS-SS-Diazirine cross-linker (spacer arm length 
1.35 nm) was from Thermo Scientific Pierce; protein 
G-agarose from Roche; siRNA-A (sc-37007) and mouse 
PGAM2 siRNA (sc-152183) were obtained from Santa 
Cruz Biotechnology. Cell culture media and supplements, 
anti-rabbit FITC-conjugated (F6005) and anti-goat FITC-
conjugated (F9012) antibodies and all other reagents were 
purchased from Sigma. 
Cell culture
The KLN-205 cells were cultured on coverslips 
in Eagle’s Minimal Essential Medium supplemented 
with L-glucose (5 mM), L-glutamine (2 mM), 10% 
(v/v) non-essential amino acids, penicillin (100 units/
ml), streptomycin (100 mg/ml), and 10% (v/v) fetal 
bovine serum (standard medium) at 37ºC and in 5% 
CO2 atmosphere. To test the effect of various biological 
signals on nuclear localization of PGAM, after 48 h of the 
KLN-205 cells culture, the standard culture medium was 
replaced with serum-free medium for 48 h. Then the cells 
were cultured in the serum-free medium supplemented 
with insulin (0.2 µM), insulin and wortmannin (the 
inhibitor of phosphoinositide 3-kinase; 1µM) or with 
IGF-1 (0.013 µM) for 24 h and localization of PGAM was 
examined using immunofluorescent methods (as described 
below). Alternatively, the KLN-205 cells were cultured 
for 2 hours in the standard medium supplemented with 
actinomycin D (0.04 µg/ml or 2.5 µg/ml), roscovitine (20 
µM) or etoposide (300 µM).
Human non-small cell lung carcinoma (NSCLC) 
cells were cultured as described in [26]. All the 
procedures used to acquire the cells were approved by the 
Commission of Bioethics at Wroclaw Medical University. 
HL-1 cardiomyocyte cell line was cultured as described 
before [27]. Mouse astrocytes were isolated and cultured 
as described in [28]. The protocol of isolation of mouse 
cells and tissues was approved by the II Local Scientific 
Research Ethical Committee, Wroclaw University of 
Environmental and Life Sciences (permission #118/2010). 
These cells were used in the experiments of PGAM 
localization by immunofluorescent or immunoperoxidase 
method.
Tissue sections
Histologically proven archival human breast cancer 
tissue samples embedded in paraffin were kindly provided 
by Piotr Dziegiel from Department of Histology and 
Embryology, Wroclaw Medical University, Wroclaw, 
Poland. PGAM localization in the slices was examined by 
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immunoperoxidase method using goat antibodies specific 
to C-terminal peptide of PGAM, anti-goat antibodies 
conjugated to biotin and ExtrAvidin®−Peroxidase. The 
3,3-diaminobenzidine was used as a peroxidase substrate.
RNase treatment
The cells cultured in the presence or in the absence 
of serum were briefly treated with 0.01% (v/v) Triton 
X-100 in Hanks Balanced Salt Solution (HBSS), washed 
thoroughly with HBSS and incubated with 1mg/ml RNase 
A for 30 minutes at RT. Then the cells were washed, fixed 
in paraformaldehyde and localization of PGAM was 
determined using the immunofluorescent method.
Immunofluorescence and confocal microscopy
The cells were fixed in 4% paraformaldehyde and 
permeabilized in 0.1% (v/v) Triton X-100 in PBS. After 
incubation with 5% (w/v) BSA in PBS which blocks 
unspecific interactions of antibodies with cells, the cells 
were incubated with goat antibodies specific to C-terminal 
peptide of PGAM (0.5 µg/ml) or with rabbit anti-PGAM 
serum (100 µg/ml) directed against the whole PGAM 
molecule (produced and tested as described in [29] and 
with FITC-conjugated secondary antibodies (1:1000). 
Then the cells were counterstained with propidium iodide 
(PI, 0.2 µg/ml), embedded in Fluoshield mounting medium 
and examined with the FV1000 confocal microscope 
(Olympus) equipped with diode lasers, the Plan Apo 
60×/1.4NA Oil objective and appropriate filter sets. All 
images were acquired using the Sequential Scan option. 
In control reactions, the primary antibodies were omitted.
PGAM2 purification and fluorescent labeling
Phosphoglycerate mutase from rabbit skeletal 
muscle was purified to homogeneity according to [29]. 
Fluorescently labeled enzyme (PGAM2-FITC) was 
obtained by modification of the protein with fluorescein 
isothiocyanate (FITC) as described by Goding [30]. 
The lack of proteolysis of the labeled protein was 
determined by SDS–PAGE. The number of fluorochrome 
molecules conjugated to the enzyme was estimated 
spectrophotometrically to be 1.9 FITC molecules per 
monomer of PGAM2.
Transfection of cells with PGAM2-FITC
Transfection of the KLN-205 cells with 3 µg of 
FITC-labeled rabbit muscle PGAM2 (the amino-acid 
sequences of rabbit and mouse PGAM2 show 95% 
identity) was performed using the ProteoJuice Protein 
Transfection Reagent as described previously [31]. After 
3 hours of cell transfection performed in serum-free 
culture medium, the medium was supplemented with 5% 
serum for 12 hours. Then the cells were washed, fixed 
in paraformaldehyde, counterstained with propidium 
iodide and examined using the confocal microscope. 
Alternatively, to facilitate the exchange of PGAM2-FITC 
with native PGAM molecules within nucleolar structures, 
the cells were transfected with 3 µg of PGAM2-FITC and 
1µg of RNase A. In control experiments, FITC-conjugated 
BSA was used instead of PGAM2-FITC.
Isolation of nucleoli and identification of PGAM 
by mass spectrometry
Nucleoli were isolated from the KLN-205 cells 
cultured in the presence or absence of serum according 
to method described in [32], and analyzed using nano-
high performance liquid chromatography combined 
with tandem mass spectrometry (nano-HPLC/MS/MS) 
with Amazon ETD mass spectrometer (Bruker Daltonik, 
Bremen, Germany) as described earlier [33]; for detailed 
methods see in Supplementary data 1).
Identification of PGAM-interacting proteins
To identify PGAM-interacting protein in nucleoli, 
KLN-205 cells grown on a 100 mm Petri dishes were 
treated with a membrane-permeable cross-linker as we 
described previously [34]. Subsequently, nucleoli were 
isolated and nucleolar proteins were extracted according 
to [35]. The obtained nucleolar extract was incubated 
with the antibodies against C-terminal region of PGAM 
bound to protein G-agarose beads, overnight at 4ºC, 
under agitation. Subsequently, the beads were thorougly 
washed to remove any unspecifically bound proteins and 
the PGAM–cross-linked proteins complexes were eluted 
with the urea buffer (20 mM Tris pH 7.5, RT, 100 mM 
NaCl, 8 M urea). The complexes were then analysed 
comercially with the ESI–MS at the Mass Spectrometry 
Laboratory (Institute of Biochemistry and Biophysics, 
Polish Academy of Sciences, Warsaw).
Silencing of PGAM2 gene expression
The commercially prepared mouse PGAM2 siRNA 
was used to silence the PGAM2 gene expression in 
KLN205 and HL-1 cells, according to the manufacturer’s 
instructions. As a control, the siRNA-A consisting of 
a scrambled sequence that does not lead to the specific 
degradation of any known cellular mRNA was used. 
Expression of PGAM1 and PGAM2 genes in these cells 




Detection of global RNA synthesis in KLN-205 cells 
(untreated and with the silenced expression of PGAM2 
gene) was performed using the Click-iT® RNA Alexa 
Fluor® 594 Imaging Kit, according to procedure provided 
by the manufacturer, and visualized with the confocal 
microscope. The cells were fed with 5-ethynyl uridine 
which was actively incorporated in the newly synthesized 
RNA. The level of this synthesis was then detected with 
azide-modified fluorochrome, Alexa Fluor® 594. DNA was 
counterstained with Hoechst 33342 provided with the kit.
Imaging of cell cycle stage
NSCLC cells were grown on coverslips to 70% 
confluence and then transduced with Premo™ FUCCI 
Cell Cycle Sensors (80 particles per cell) according to 
manufacturer’s instruction. For induction of nucleolar 
stress, cells were exposed to 0.04 µg/ml ActD as described 
above. Then they were fixed with paraformaldehyde and 
examined with confocal microscope.
The titers of PGAM isozymes in mouse tissues
Concentrations of PGAM1 and PGAM2 in whole 
cell tissue lysates were calculated by means of the ‘Total 
Protein Approach’ [36] using recently published datasets 
[37-38]. 
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